Fatty liver disease
Conditions
Interventions
Fatty liver disease group:Prescription for relieving liver stagnation
Diabetes mellitus with fatty liver disease group:Prescription for relieving liver stagnation
Viral hepatitis with fatty liver disease group:Prescription for relieving liver stagnation
Control group:Hawthorn granules
Sponsors
The Sixth People's Hospital of Shenyang
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Metabolism-related fatty liver disease (2) Age18-65 (3) Signed informed consent
Exclusion criteria
Exclusion criteria: (1) Patients with fatty liver disease caused by other causes; (2) pregnant or lactating women and women who plan to become pregnant during the study period; (3) allergic to the test drug; (4) Patients with mental abnormalities that cannot cooperate with this study, or patients with unstable epilepsy; (5) patients with serious heart, brain, lung, kidney, hematopoietic and other systemic diseases; (6) those who are not suitable to be observers of drug trials, or cannot cooperate with treatment, and are difficult to accurately evaluate the efficacy and safety of drugs; (7) Other conditions considered unsuitable for inclusion by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| liver function;fibroscan;liver ultrasound; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glucose;blood fat;Blood routine test;IL-2;Chitinase 3-like protein 1;PCT; | — |
Countries
China
Contacts
Public ContactYan Wang
The Sixth People's Hospital of Shenyang
Outcome results
None listed